Funding Support: Orum Therapeutics has successfully secured 145 billion KRW (approximately $100 million) in convertible preferred stock investments, primarily led by KB Investment, signaling strong confidence from investors in its scientific direction and establishing a solid foundation for the company's next growth phase.
Program Advancement: This funding will support the clinical evaluation of ORM-1153 and additional programs, propelling Orum's innovations in oncology and other serious diseases, thereby reinforcing its leadership position in next-generation DACs.
Infrastructure Expansion: The capital will be utilized to expand Orum's scientific and operational infrastructure, enhancing its capabilities in DAC projects based on selectivity, potency, and rational payload design, which will strengthen its competitive edge in the market.
Investor Confidence: New investors, including Boston-based Weiss Asset Management and Korea Investment Partners, demonstrate recognition of Orum's long-term potential in biotechnology, further enhancing its operational capabilities in the global market.
KB
$84.21+Infinity%1D
Analyst Views on KB
Wall Street analysts forecast KB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KB is 105.84 USD with a low forecast of 105.84 USD and a high forecast of 105.84 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast KB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KB is 105.84 USD with a low forecast of 105.84 USD and a high forecast of 105.84 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 84.040
Low
105.84
Averages
105.84
High
105.84
Current: 84.040
Low
105.84
Averages
105.84
High
105.84
No data
About KB
KB Financial Group Inc is a Korean-based company principally engaged in the financial business. The Company operates its business through six segments. The Banking segment consists of retail banking services provided by Kookmin Bank. This segment is engaged in the lending and receiving of large corporations, small and medium-sized businesses, SOHO and household customers, the investment of securities and derivatives, and financing, among others. The Credit Card segment operates credit sales, cash advances and card loans, among others. The Securities segment is engaged in the trading, consignment and acquisition of securities. The Non-life Insurance segment is engaged in the non-life insurance. The Life Insurance segment is engaged in the life insurance. The other segment is engaged in the maintenance of computer-related equipment and systems, the investigation of credit and the collection of debt, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
